hidden pixel

Potassium Channel Blocker Information

Potassium channel blockers are agents which interfere with conduction through potassium channels.

Contents

Arrhythmia

Effect of class III antiarrhythmic agent on cardiac action potential.

Potassium channel blockers used in the treatment of cardiac arrhythmia are classified as class III antiarrhythmic agents.

Mechanism

Class III agents predominantly block the potassium channels, thereby prolonging repolarization.[1] More specifically, their primary effect is on IKr.[2]

Since these agents do not affect the sodium channel, conduction velocity is not decreased. The prolongation of the action potential duration and refractory period, combined with the maintenance of normal conduction velocity, prevent re-entrant arrhythmias. (The re-entrant rhythm is less likely to interact with tissue that has become refractory).

Class III antiarrhythmic agents exhibit reverse use dependent prolongation of the action potential duration (Reverse use-dependence). This means that the refractoriness of the ventricular myocyte increases at lower heart rates. This increases the susceptibility of the myocardium to early after-depolarizations (EADs) at low heart rates. Antiarrhythmic agents that exhibit reverse use-dependence are more efficacious at preventing a tachyarrhythmia than converting someone into normal sinus rhythm. Because of the reverse use-dependence of class III agents, at low heart rates class III antiarrhythmic agents may paradoxically be more arrhythmogenic.

Examples and uses

Side effects

These agents include a risk of torsades de pointes.[5]

Other uses

Potassium channel blockers have also been approved for use in the treatment of multiple sclerosis.[6]

See also

References

  1. ^ Lenz TL, Hilleman DE (July 2000). "Dofetilide, a new class III antiarrhythmic agent". Pharmacotherapy 20 (7): 776–86. doi:10.1592/phco.20.9.776.35208. PMID 10907968.
  2. ^ Riera AR, Uchida AH, Ferreira C, et al. (2008). "Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome". Cardiol J 15 (3): 209–19. PMID 18651412.
  3. ^ "Milestones in the Evolution of the Study of Arrhythmias". http://www.medscape.com/viewarticle/412798_3.
  4. ^ Sahara M, Sagara K, Yamashita T, Iinuma H, Fu LT, Watanabe H (August 2003). "Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach" ( – Scholar search). Circ. J. 67 (8): 712–4. doi:10.1253/circj.67.712. PMID 12890916. http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/67.712?from=PubMed.
  5. ^ "Introduction: Arrhythmias and Conduction Disorders: Merck Manual Professional". http://www.merck.com/mmpe/sec07/ch075/ch075a.html.
  6. ^ Judge SI, Bever CT (July 2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID 16472864. http://linkinghub.elsevier.com/retrieve/pii/S0163-7258(05)00228-7.
· · Channel blocker: potassium channel blockers
Antiarrhythmic III/delayed rectifier benzofuran (Amiodarone) • quaternary ammonium (Bretylium) • naphthalene (Bunaftine) • phenethylamine (Dofetilide) • sulfonamide (Ibutilide) • pyrimidinone (Nifekalant) • ethanolamine (Sotalol) • cyclopropane (Tedisamil) • E-4031
Other/ungrouped/unknown aminopyridines (3,4-Diaminopyridine, 4-Aminopyridine) • indole (Linopirdine, Paxilline) • quaternary ammonium (Tetraethylammonium) • peptide (Maurotoxin, Charybdotoxin)
· · Antiarrhythmic agents (C01B)
Channel blockers
class I (Na+ channel blockers)
class Ia (Phase 0→ and Phase 3→) Procainamide # • Quinidine # • AjmalineDisopyramidePrajmalineLorajmineSparteine
class Ib (Phase 3←) IV (Lidocaine #) • enteral (Mexiletine, Tocainide, Aprindine)
class Ic (Phase 0→) EncainideFlecainideLorcainideMoricizine‡ • Propafenone
class III (Phase 3→, K+ channel blockers) AmiodaroneDronedaroneBretyliumBunaftineDofetilideIbutilideNifekalantSotalolTedisamilVernakalantE-4031
class IV (Phase 4→, Ca2+ channel blockers) Verapamil # • Diltiazem
Receptor agonists and antagonists
class II (Phase 4→, β blockers) PropranololNadololPindololcardioselective (Atenolol, Metoprolol, Acebutolol, Esmolol)
A1 agonist Adenosine
M2 muscarinic antagonist: AtropineQuinidineDisopyramide muscarinic agonist: Digoxin
α receptors QuinidineVerapamilAmiodaroneBretylium
Ion transporters
Na+ / K+-ATPase Digoxin
#WHO-EM. Withdrawn from market. Clinical trials: Phase III. §Never to phase III

: HRT

//

//, /

, drug (///),

Categories: Potassium channel blockers

 

The above information uses material from Wikipedia and is licensed under the GNU Free Documentation License.
Some facts may not have been fully verified for accuracy. [Disclaimers]
This page was last archived by our server on Sun Jun 12 00:12:59 2011.
Displaying this page or its contents does not use any Wikimedia Foundation's resources.
The owners of this site proudly support the Wikimedia Foundation.